JNJ 26854165

Drug Profile

JNJ 26854165

Alternative Names: JNJ-26854165

Latest Information Update: 09 Apr 2010

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antineoplastics; Benzodiazepinones; Indoles; Pyridines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors; Proto-oncogene protein c-mdm2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 24 Oct 2008 Interim adverse events and pharmacokinetics data from a phase I trial in Cancer presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
  • 03 Jun 2008 Preclinical pharmacodynamics data presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 16 Apr 2008 Preclinical pharmacodynamics data presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top